Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2

PHASE3CompletedINTERVENTIONAL
Enrollment

331

Participants

Timeline

Start Date

February 7, 2013

Primary Completion Date

November 27, 2013

Study Completion Date

December 19, 2013

Conditions
Hyperlipidemia
Interventions
BIOLOGICAL

Evolocumab

Administered by subcutaneous injection

DRUG

Placebo

Administered by subcutaneous injection

Trial Locations (39)

1685

Research Site, Midrand

2015

Research Site, Camperdown

2193

Research Site, Johannesburg

4153

Research Site, Reinach

6000

Research Site, Perth

7505

Research Site, Parow

7925

Research Site, Observatory

8011

Research Site, Christchurch

14004

Research Site, Córdoba

28040

Research Site, Madrid

43204

Research Site, Reus

44093

Research Site, Nantes

45227

Research Site, Cincinnati

50009

Research Site, Zaragoza

50937

Research Site, Cologne

69677

Research Site, Bron

75651

Research Site, Paris

85258

Research Site, Scottsdale

V6Z 1Y6

Research Site, Vancouver

N6A 5K8

Research Site, London

G7H 7K9

Research Site, Chicoutimi

H2W 1R7

Research Site, Montreal

H3A 1A1

Research Site, Montreal

Unknown

Research Site, New Territories

3813 TZ

Research Site, Amersfoort

1091 AC

Research Site, Amsterdam

1105 AZ

Research Site, Amsterdam

2803 HH

Research Site, Gouda

9713 GZ

Research Site, Groningen

1625 HV

Research Site, Hoorn

5022 GC

Research Site, Tilburg

3584 CX

Research Site, Utrecht

0373

Research Site, Oslo

111 35

Research Site, Stockholm

141 86

Research Site, Stockholm

CV2 2DX

Research Site, Coventry

SE1 7EH

Research Site, London

W6 8RF

Research Site, London

M13 9WL

Research Site, Manchester

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY